| |
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation |
| Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N |
|
|
| |
Record Status This is a high quality systematic review involving CRD that meets the criteria for inclusion on DARE. As CRD reviews are of high quality a structured abstract will be written presenting a brief summary of the review methods, the results and conclusions. Bibliographic details Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2011; 15(10): 1-134 Indexing Status Subject indexing assigned by NLM MeSH Adalimumab; Anti-Inflammatory Agents, Non-Steroidal /economics /therapeutic use; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Antirheumatic Agents /economics /therapeutic use; Arthritis, Psoriatic /drug therapy /economics /pathology; Costs and Cost Analysis; Etanercept; Great Britain; Humans; Immunoglobulin G /economics /therapeutic use; Infliximab; Prognosis; Quality-Adjusted Life Years; Receptors, Tumor Necrosis Factor /therapeutic use; Severity of Illness Index; Treatment Outcome AccessionNumber 12011001532 Date bibliographic record published 01/06/2011 |
| |
|
|
